related documents
- A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. Conferences
- A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). Conferences
- A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends. Conferences
- Analytical validation of StrandAdvantage solid tumor NGS test. Conferences
- Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study. Conferences
- Can oncology readmissions be reduced? The Cleveland Clinic experience. Conferences
- Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. Conferences
- Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). Conferences
- Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis. Conferences
- Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) Conferences
- Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients. Conferences
- Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC). Conferences
- NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. Conferences
- Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study. Conferences
- Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. Conferences
- Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). Conferences
- Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. Conferences
- Physicians' attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada). Conferences
- Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. Conferences
- The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. Conferences
- The role of biomarkers in improving clinical trial success: A study of 1,079 oncology drugs. Conferences
- Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis Conferences
- Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. Conferences